Titer determination after vaccination with an adjuvanted herpes zoster subunit vaccine in patients with liver cirrhosis and after liver transplantation: a prospective cohort study - TiZa

Institut für Allgemeinmedizin des Universitätsklinikums Essen0 个研究点目标入组 308 人开始时间: 2022年11月9日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients of the liver transplant outpatient clinic of the University Medical Center Essen, who have liver cirrhosis Child A or B or have undergone liver transplantation and are older than 50 years.
•Immunocompetent control group: patients without a chronic disease mentioned in the exclusion criteria and without immunosuppression with medication, who are 60-70 (max. 75) years old.

•Varicella seronegativity, previous vaccination with Shingrix® or Zostavax®, acute liver failure, drug immunosuppression in patients with chronic liver cirrhosis, liver transplantation less than six months ago, lack of knowledge of German or inability to translate, allergy to one of the components of the Shingrix® vaccine, life expectancy <6 months, pregnancy, HIV infection.
•Immunocompetent control group additionally in the presence of at least one of the following diseases/circumstances: rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), bronchial asthma, diabetes mellitus, congenital or acquired immunodeficiency or immunosuppression/medical immunosuppression (e.g. cortisone as tbl. or i.v., methotrexate (MTX®), leflunomide (Arava®)), HIV infection, chronic alcohol addiction, chronic liver disease or condition after hepatitis.

发起方

Institut für Allgemeinmedizin des Universitätsklinikums Essen